Parabilis Medicines raises $670.0M IPO (United States, Jun 2026)
Reach the investors backing rounds like this
Backed by Regeneron Pharmaceuticals · verified emails and LinkedIn on Datapile
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Parabilis Medicines is a biotechnology startup focused on developing therapies for 'undruggable' targets, particularly in cancer treatment. The company has raised significant funding to advance its innovative peptide drugs, known as 'Helicons', which aim to target difficult-to-reach cancer-driving proteins. Their most advanced candidate, zolucatetide, is set to enter Phase 3 trials for desmoid tumors in 2027.
Parabilis sets a record with a $670M biotech IPO BioPharma Dive
| Aug 24, 2026 | Generalist AI | $200.0M | Series B | United States |
| Aug 24, 2026 | General Intuition | $320.0M | Series C | United States |
| Aug 24, 2026 | Kita | $4.5M | Seed | United States |
| Aug 24, 2026 | Xenter | $58.3M | Series B | United States |
19,767 investors back startups in United States
You just read who funded Parabilis Medicines. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.